← Back to contracts

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

US National Institutes of Health (NIH) grant open #PAR-25-070
Response due Jan 07, 2027 · 00:00 UTC

Summary

This NIH funding opportunity announcement (FOA) solicits R21 exploratory/developmental research grants investigating the biological mechanisms by which incretin mimetics (e.g., GLP-1 receptor agonists, GIP/GLP-1 dual agonists) may impact cancer risk. Clinical trials are explicitly excluded from this mechanism. The program aims to advance understanding of how this increasingly prevalent drug class may modulate oncogenic or tumor-suppressive pathways.

What they want

Technical requirements
  • Research must focus on mechanisms linking incretin mimetic use to cancer risk
  • Clinical trials are not allowed under this funding mechanism (R21)
  • Must comply with NIH R21 exploratory/developmental research grant requirements

How they evaluate

Submission: Grants.gov electronic submission portal

Risks & flags

  • No dollar values or budget caps stated — applicants should consult the full PAR-25-070 announcement for R21 budget limits
  • Extremely long open window (over 2 years) suggests multiple receipt/review cycles — confirm exact due dates in full FOA

Market context

inferred from NAICS
Professional, Scientific & Technical Services
NAICS 541714
US market size
$2.0T
Typical award
$25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Mechanisms that Impact Cancer Risk with Us…
Due Jan 07
Onboard ↗